The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions.

IF 1.9 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Heart International Pub Date : 2020-12-23 eCollection Date: 2020-01-01 DOI:10.17925/HI.2020.14.2.86
Gunasekaran Sengottuvelu, Vijay Kumar, Ashok Seth
{"title":"The Myval Transcatheter Heart Valve System for the Treatment of Severe Aortic Stenosis - Current Evidence and Future Directions.","authors":"Gunasekaran Sengottuvelu,&nbsp;Vijay Kumar,&nbsp;Ashok Seth","doi":"10.17925/HI.2020.14.2.86","DOIUrl":null,"url":null,"abstract":"<p><p>Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The Myval™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical features of this transcatheter valve, pre-clinical studies and evidence from the first-in-human trial. We also provide a brief overview of planned clinical trials and registries.</p>","PeriodicalId":12836,"journal":{"name":"Heart International","volume":"14 2","pages":"86-91"},"PeriodicalIF":1.9000,"publicationDate":"2020-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524723/pdf/heart-int-14-86.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/HI.2020.14.2.86","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 4

Abstract

Transcatheter aortic valve replacement has revolutionised the treatment of aortic valve disease. The Myval™ device (Meril Life Sciences Pvt. Ltd., Gujarat, India) is a CE-marked, next-generation balloon-expandable transcatheter heart valve, designed for the treatment of severe aortic valve stenosis. This review illustrates the salient technical features of this transcatheter valve, pre-clinical studies and evidence from the first-in-human trial. We also provide a brief overview of planned clinical trials and registries.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Myval经导管心脏瓣膜系统治疗严重主动脉瓣狭窄-目前的证据和未来的方向。
经导管主动脉瓣置换术彻底改变了主动脉瓣疾病的治疗。Myval™装置(Meril Life Sciences Pvt. Ltd., Gujarat, India)是ce认证的下一代球囊可膨胀经导管心脏瓣膜,专为治疗严重主动脉瓣狭窄而设计。这篇综述阐述了这种经导管瓣膜的突出技术特点、临床前研究和首次人体试验的证据。我们还提供了计划的临床试验和注册的简要概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Heart International
Heart International Medicine-Cardiology and Cardiovascular Medicine
CiteScore
0.90
自引率
0.00%
发文量
9
审稿时长
7 weeks
期刊最新文献
Efficacy of Commonly Used 3D Mapping Systems in Acute Success Rates of Catheter Ablation Procedures. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Femoral Neck Osteoporosis Is Associated with a Higher Odds of Coronary Artery Disease in Indian Postmenopausal Women: A Cross-sectional Study from a Teaching Hospital in Southern India. Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies. A Comprehensive Evaluation of the NAVITOR Transcatheter Aortic Valve Replacement System.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1